Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial
Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro, Giuliano Giová Volpiani, Caroline Cândida Carvalho de Oliveira, Valéria Cristina Resende Aguiar, Elizabeth Rodrigues, Marcone Lima Sobreira, Edwaldo Édner Joviliano, Cesar Dusilek, Kenji Itinose, Rogério Aparecido Dedivitis, André Sementilli Cortina, Suzanna Maria Viana Sanches, Nara Franzin de Moraes, Paulo Fernando Guimarães Morando Marzocchi Tierno, André Luiz Malavasi Longo de Oliveira, Adriano Tachibana, Rodrigo Caruso Chate, Marcus Vinícius Barbosa Santos, Bruno Bezerra de Menezes Cavalcante, Ricardo Moreira, Chang Chiann, Alfonso Tafur, Alex C. Spyropoulos, Renato D. Lópes
Topics & Concepts
MedicineRivaroxabanRegimenPulmonary embolismAdverse effectMyocardial infarctionThrombosisStroke (engine)Venous thrombosisIntensive care medicineClinical trialInternal medicineWarfarinAtrial fibrillationMechanical engineeringEngineeringCOVID-19 Clinical Research StudiesVenous Thromboembolism Diagnosis and ManagementHeparin-Induced Thrombocytopenia and Thrombosis